In a landmark study, Medical College of Wisconsin researchers in Milwaukee report that drugs used to inhibit a specific fatty acid in rat brains with glioblastoma-like tumors not only reduced new blood vessel growth and tumor size dramatically, but also prolonged survival. The study is the featured cover story of the August, 2008 Journal of Cerebral Blood Flow & Metabolism.
"These rat model tumors were developed from human glioblastoma tumor cells and closely mimic human tumors in growth patterns and response to therapy," says lead researcher David Harder, Ph.D., Kohler Co. Professor in Cardiovascular Research. "The concept of targeting blood vessels that feed tumors as an approach to limit tumor growth is not a novel idea," he says. "However, blocking the specific fatty acid described in this study is novel, and holds great promise for use in humans."
Malignant gliomas are very aggressive tumors of the central nervous system, resistant to chemotherapy and radiation, and account for about half of the 350,000 brain tumors currently diagnosed in the U.S.
Dr. Harder is also professor of physiology, associate dean for research and director of the Medical College's Cardiovascular Research Center. He believes that further studies, demonstrating that such drugs work in humans may reveal that higher concentrations or infusions over longer periods of time may be more effective than the results reported in this study.
"If survival time could be extended, with a combination of surgical therapy and infusion with similar drugs, this could be a significant treatment option," he says.
Earlier studies from the Harder lab have shown that specific fatty acids generated in the brain induce new blood vessel growth known as angiogenesis. Harder and colleagues designed these studies on the premise that all cells, including cancer cells, require oxygen for growth and that blocking formation of specific fatty acids would decrease blood vessel growth and oxygen supply to tumors, retarding their growth.
In their current study, Dr. Harder and colleagues compared three sets of rats with induced tumors, two groups using either one of two inhibitor drugs, 17-ODYA or miconazole, to block the fatty acid CYP epoxygenase and a control group, receiving a placebo. Drugs were infused directly into the tumors over an extended period of time, using specially-designed miniature osmotic pumps and a very small burr hole in the skull. The pumps, similar to those used in humans, were buried just beneath the skin through a tiny incision.
Compared to the control group, tumor size in the drug-infused groups was reduced by an average 50 to 70 percent, and survival time increased by five to seven days, equivalent to three to four months in terms of human survival.
"These pumps have been used in humans for other diseases and can be designed for delivery of these drugs as well," says Dr. Harder. "We believe they can be used to deliver drugs to block angiogenesis in complex human tumors such as glioblastomas."
Eileen La Susa | EurekAlert!
Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT
Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
06.12.2016 | Power and Electrical Engineering
06.12.2016 | Earth Sciences
06.12.2016 | Physics and Astronomy